After receiving FDA clearance for AI software that can detect brain bleeds from CT images, MaxQ AI has announced a deal to integrate the software with medical imaging platforms.
MaxQ AI, a clinical diagnostics intelligence platform company based in Tel Aviv, Israel, announced its new distribution agreement with Samsung NeuroLogica on Tuesday. The deal allows MaxQ AI’s Accipio Ix Intracranial Hemorrhage software to be integrated into with NeuroLogica’s medical imaging hardware in the U.S. and European acute care marketplace.
The agreement will “further accelerate the commercialization of our AI-powered solutions for the acute care market," Chris Schnee, senior vice president of commercial operations for MaxQ AI, said in a prepared statement.
"Designed for seamless integration into CT and PACS systems, our platform coupled with the unique mobile CT offering of Samsung Neurologica, will bring critical life-saving decisions directly to patients in mobile stroke units and to the bedside of acute care hospital departments,” he said.
Earlier this month, the FDA gave 510(k) clearance to the software, allowing it to be sold commercially in the United States. The software uses AI technology to automatically analyze non-contrast head CT images and should help physicians prioritize patients who show signs of a brain bleed.
"AI has the potential to revolutionize diagnostics, and this collaboration will bring that potential into the patient's room through our point of care CT systems," David Webster, chief operating officer of NeuroLogica, said in a statement.